2026 Dyslipidemia Guideline Adds 25 Million Statin Candidates
This NHANES modeling study quantifies how the 2026 ACC/AHA dyslipidemia guideline expands statin eligibility and exposes a large treatment-intensification gap that anticoagulation and cardiology pharmacists will help manage.
2026 guidelines expand statin eligibility for millions of adults.
The updated 2026 dyslipidemia guidelines significantly increase the number of adults eligible for lipid-lowering therapy (LLT), potentially impacting clinical management at a population level. Under the 2026 guideline, 40.5% of adults are eligible for LLT compared to 25.7% under the 2018 guideline, affecting an additional 24.5 million adults. The 2026 guidelines will lead to increased statin therapy initiation and intensification to meet new LDL-C goals, requiring adjustments in current treatment practices. New guidelines significantly expand LLT eligibility, prompting increased statin use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Sayed A, Peterson ED, Navar AM Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults. Journal of the American College of Cardiology. 2026. doi:10.1016/j.jacc.2026.06.037
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.